

---

---

# <sup>18</sup>F-FDG PET/CT Optimizes Treatment in *Staphylococcus Aureus* Bacteremia and Is Associated with Reduced Mortality

Marvin A.H. Berrevoets\*<sup>1</sup>, Ilse J.E. Kouijzer\*<sup>1</sup>, Erik H.J.G. Aarntzen<sup>2</sup>, Marcel J.R. Janssen<sup>2</sup>, Lioe-Fee De Geus-Oei<sup>3,4</sup>, Heiman F.L. Wertheim<sup>5</sup>, Bart-Jan Kullberg<sup>1</sup>, Jaap Ten Oever<sup>1</sup>, Wim J.G. Oyen<sup>2,6</sup>, and Chantal P. Bleeker-Rovers<sup>1</sup>

<sup>1</sup>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>2</sup>Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>3</sup>Department of Radiology and Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands; <sup>4</sup>MIRA Institute for Biomedical Technology and Technical Medicine, Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands; <sup>5</sup>Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands; and <sup>6</sup>Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom

---

Metastatic infection is an important complication of *Staphylococcus aureus* bacteremia (SAB). Early diagnosis of metastatic infection is crucial, because specific treatment is required. However, metastatic infection can be asymptomatic and difficult to detect. In this study, we investigated the role of <sup>18</sup>F-FDG PET/CT in patients with SAB for detection of metastatic infection and its consequences for treatment and outcome. **Methods:** All patients with SAB at Radboud University Medical Center were included between January 2013 and April 2016. Clinical data and results of <sup>18</sup>F-FDG PET/CT and other imaging techniques, including echocardiography, were collected. Primary outcomes were newly diagnosed metastatic infection by <sup>18</sup>F-FDG PET/CT, subsequent treatment modifications, and patient outcome. **Results:** A total of 184 patients were included, and <sup>18</sup>F-FDG PET/CT was performed in 105 patients, of whom 99 had a high-risk bacteremia. <sup>18</sup>F-FDG PET/CT detected metastatic infectious foci in 73.7% of these high-risk patients. In 71.2% of patients with metastatic infection, no signs and symptoms suggesting metastatic complications were present before <sup>18</sup>F-FDG PET/CT was performed. <sup>18</sup>F-FDG PET/CT led to a total of 104 treatment modifications in 74 patients. Three-month mortality was higher in high-risk bacteremia patients without <sup>18</sup>F-FDG PET/CT performed than in those in whom <sup>18</sup>F-FDG PET/CT was performed (32.7% vs. 12.4%,  $P = 0.003$ ). In multivariate analysis, <sup>18</sup>F-FDG PET/CT was the only factor independently associated with reduced mortality ( $P = 0.005$ ; odds ratio, 0.204; 95% confidence interval, 0.066–0.624). A higher comorbidity score was independently associated with increased mortality ( $P = 0.003$ ; odds ratio, 1.254; 95% confidence interval, 1.078–1.457). **Conclusion:** <sup>18</sup>F-FDG PET/CT is a valuable technique for early detection of metastatic infectious foci, often leading to treatment modification. Performing <sup>18</sup>F-FDG PET/CT is associated with significantly reduced 3-mo mortality.

**Key Words:** <sup>18</sup>F-FDG PET/CT; *Staphylococcus aureus*; metastatic infection

J Nucl Med 2017; 58:1504–1510

DOI: 10.2967/jnumed.117.191981

**S***Staphylococcus aureus* bacteremia (SAB) is a severe infection known for its high morbidity and is associated with a 30-d overall mortality of 20% (1). An important complication of SAB is metastatic infection, with a reported incidence between 16% and 68% (2–7). Known risk factors for development of metastatic infection in SAB patients are community acquisition of the bacteremia, signs of infection present for more than 48 h before initiation of appropriate antibiotic treatment, fever more than 72 h after initiation of appropriate antibiotic treatment, and positive blood cultures more than 48 h after initiation of appropriate antibiotic treatment (3). Early detection of metastatic infection is crucial, because morbidity and mortality are higher in the presence of these foci, probably due to incomplete eradication during treatment (8). However, metastatic infectious foci are often asymptomatic. In up to one third of patients with Gram-positive bacteremia and metastatic foci, localizing signs and symptoms are absent (8).

During the past years, <sup>18</sup>F-FDG PET/CT has been extensively used in diagnosing infectious diseases (IDs). Previous studies on the value of <sup>18</sup>F-FDG PET/CT in metastatic infection have demonstrated that <sup>18</sup>F-FDG PET/CT detects infectious foci in patients with bacteremia or infective endocarditis and leads to a decrease in relapse and mortality rate (9,10). Furthermore, <sup>18</sup>F-FDG PET/CT has shown to be cost-effective in patients with Gram-positive bacteremia (11). The previous studies, however, did not report on how <sup>18</sup>F-FDG PET/CT optimizes treatment in SAB, whereas the positive effect on outcome is undoubtedly caused by treatment modification. Therefore, the aim of this study was to investigate the diagnostic value of <sup>18</sup>F-FDG PET/CT for newly diagnosed metastatic infection, subsequent treatment modifications, and outcome in patients with SAB, with a focus on patients with high-risk bacteremia.

## MATERIALS AND METHODS

### Study Design and Patients

This retrospective cohort study was performed at Radboud University Medical Center, Nijmegen, The Netherlands. All consecutive adult SAB cases between January 2013 and April 2016 were included. SAB was defined as 1 or more blood cultures positive for *S. aureus*. SAB cases were designated hospital-acquired if patients had been admitted for at least 48 h before the first positive blood culture, or as community-acquired in all other cases. Exclusion criteria were

---

Received Feb. 17, 2017; revision accepted Mar. 13, 2017.  
For correspondence or reprints contact: Marvin A.H. Berrevoets, Department of Internal Medicine and Infectious Diseases, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.  
E-mail: Marvin.Berrevoets@radboudumc.nl  
\*Contributed equally to this work.  
Published online Mar. 23, 2017.  
COPYRIGHT © 2017 by the Society of Nuclear Medicine and Molecular Imaging.

pregnancy and death within 48 h after the first positive blood culture with *S. aureus*. According to the Dutch law, this study was exempt from approval by an ethics committee, because of the retrospective character of this study and the anonymous processing of data. The regional institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived.

### Data Collection

We reviewed the medical records of all patients and collected data on patient demographic characteristics; estimated prognosis of preexisting underlying disease and comorbidity according to the Charlson comorbidity score (12); and determined onset of bacteremia, presence of intravascular catheters or foreign body material, resistance of *S. aureus* to methicillin, foci of infection, and clinical parameters at SAB onset, diagnostic investigations, antimicrobial therapy, and outcomes. The data were retrieved electronically from clinical charts and reports of diagnostic studies (including laboratory, microbiologic, and imaging data).

### Diagnostic Workup

According to definitions established previously (3,8), cases were designated high-risk SAB if one of the following criteria for increased risk of metastatic infection was met: community acquisition of the bacteremia, signs of infection for more than 48 h before initiation of appropriate antibiotic treatment, fever more than 72 h after initiation of appropriate antibiotic treatment, positive blood cultures more than 48 h after initiation of appropriate antibiotic treatment, or already confirmed metastatic foci at the moment of presentation. For all patients with high-risk SAB, echocardiography and <sup>18</sup>F-FDG PET/CT were recommended.

An integrated PET/CT scanner (Biograph 40 mCT; Siemens Healthcare) was used. Before <sup>18</sup>F-FDG injection, patients fasted and any glucose- or insulin-containing infusions were discontinued for at least 6 h. In 66.7% of patients, a low-carbohydrate fat-allowed diet was followed 24 h before <sup>18</sup>F-FDG PET/CT. Blood glucose samples were taken from all patients before <sup>18</sup>F-FDG administration. At the time of <sup>18</sup>F-FDG injection, glucose was below 12 mmol/L in all patients, including diabetic patients. One hour after intravenous injection of an average dosage of 3.3 MBq × body weight (kg)/min/bed position of <sup>18</sup>F-FDG (Mallinckrodt Pharmaceuticals or IBA Molecular), a whole-body low-dose CT was acquired for anatomic correlation and attenuation correction of the PET data. Emission images of the same area were acquired. <sup>18</sup>F-FDG PET/CT scans were considered abnormal if focal accumulation of <sup>18</sup>F-FDG was detected. Normal test results were considered true-negative when no complicating infectious foci were diagnosed within 2 wk after <sup>18</sup>F-FDG PET/CT was performed. Normal test results were considered false-negative when a localized infectious focus was diagnosed but not reported on <sup>18</sup>F-FDG PET/CT. Abnormal test results not related to metastatic infection that were caused by a confirmed alternative diagnosis (i.e., cancer) were categorized as noninfectious relevant.

In all patients with SAB, the local antimicrobial stewardship program recommends bedside consultation by an ID specialist as well as echocardiography. Transthoracic echocardiography was used as a first-line screening technique, except for those patients with prosthetic valves, in whom transesophageal echocardiography was the first-line technique. Transesophageal echocardiography was recommended in all patients in whom transthoracic echocardiography was negative for endocarditis, especially when imaging was hampered by technical or anatomic problems. Endocarditis was defined according to the modified Duke criteria (13).

Patients were treated according to the national guideline for SAB, which is concordant with the Infectious Diseases Society of America guideline (14). However, for patients with risk factors for metastatic

foci but without evidence of endocarditis after echocardiography and without signs of metastatic infection on <sup>18</sup>F-FDG PET/CT, the institutional guideline recommends antimicrobial therapy for 2 wk. These patients were considered as having uncomplicated bacteremia instead of complicated bacteremia.

### Diagnosis and Patient Follow-up

Patient outcome and recurrent infection were assessed by reviewing patients' medical records. Patient follow-up after the end of antimicrobial therapy was at least 3 mo to capture SAB relapse, mortality, and cause of death. Patients were considered to be cured if no symptoms or signs of infection were present 3 mo after the discontinuation of antibiotic treatment. Relapse of SAB was defined as a second episode of SAB within 3 mo after the end of treatment.

### <sup>18</sup>F-FDG PET/CT and Treatment Modifications

The impact of <sup>18</sup>F-FDG PET/CT on treatment was determined by the investigators for all cases in a 2-step approach. First, treatment duration was determined on the basis of all clinical information available before <sup>18</sup>F-FDG PET/CT was performed. Second, the results of the <sup>18</sup>F-FDG PET/CT were provided, and the modifications of therapy based on these results were noted. During a weekly multidisciplinary meeting, all results of <sup>18</sup>F-FDG PET/CT scans obtained in patients with SAB were discussed with a panel of ID specialists and nuclear medicine physicians and treatment modifications based on these results were also noted in the patient's chart.

The impact of <sup>18</sup>F-FDG PET/CT on treatment was classified as follows. The first was extension of antibiotic treatment including prolonged intravenous antibiotic therapy, for example, instead of oral antibiotic therapy; addition of a second antimicrobial drug, for example, rifampin, in patients with foreign body material infection; or extension of total treatment duration, for example, in the case of joint or vascular prosthesis infection. The second classification was surgical or radiologic intervention, for example, abscess drainage, removal of foreign body material. The third classification was shortening of treatment duration. If the results of the <sup>18</sup>F-FDG PET/CT did not result in any intervention, this was also reported. To prevent interpretation bias, 2 independent physician observers reviewed hospitalization records and determined treatment modification before and after <sup>18</sup>F-FDG PET/CT results. If there was no consensus, a third independent ID specialist with broad experience in SAB and <sup>18</sup>F-FDG PET/CT made the final judgment. In patients with high-risk SAB, a comparison was made between patients who underwent <sup>18</sup>F-FDG PET/CT and patients who did not.

### Statistical Analysis

SPSS (version 22.0; SPSS, Inc.) was used for analyzing data. Descriptive statistics for continuous variables were represented as median ± SD. Unpaired Student *t* tests were used to compare continuous variables. Categorical variables were compared by use of the  $\chi^2$  test or Fisher exact test when the  $\chi^2$  test was not appropriate. Differences were considered to be statistically significant at a 2-sided *P* value of less than 0.05. To determine independent predictors of 3-mo mortality in the high-risk bacteremia group, we performed a multivariate analysis, including prognostic factors associated with a *P* value of less than 0.20 in univariate analysis. To limit the amount of variables in the model, the Charlson comorbidity score was used as a composite variable for age and comorbidity. As a composite variable for risk factors for metastatic infection, a risk score previously described by Fowler et al. (3) was used; community-acquisition, persistent fever longer than 72 h, and skin findings suggesting the presence of metastatic infection were separately scored as 1 point, and positive follow-up blood culture results were scored as 2 points.

**TABLE 1**  
Baseline Characteristics of All 184 Patients with SAB

Characteristic	No. of patients
Total	184
Male	113 (61.4)
Mean age (y)	61.1 (range, 18–80)
<b>Risk factor</b>	
Community acquisition	120 (65.2)
Treatment delay > 48 h	45 (28.1)*
Persistent fever	54 (30.7)†
Persistent positive blood cultures	39 (21.2)
Rifampin treatment	48 (26.1)
ID specialist bedside consultation	140 (76.1)
<b>Additional risk factors</b>	
Charlson comorbidity score	4.7
Diabetes mellitus	42 (22.8)
Metastatic malignancy	16 (8.7)
Immunocompromised	61 (33.2)
Joint prosthesis	26 (14.1)
Heart valve prosthesis	23 (12.5)
Vascular prosthesis	20 (10.9)
Pacemaker/ICD	18 (9.8)
Intravascular catheter	35 (19.0)
Total parenteral nutrition	19 (10.3)
TTE	104 (56.5)
TEE	64 (34.8)
TTE/TEE	123 (66.8)

\*No data available in 24 patients.

†No data available in 8 patients.

ICD = implantable cardioverter defibrillator; TTE = transthoracic echocardiography; TEE = transesophageal echocardiography.

Data in parentheses are percentages, unless otherwise specified.

## RESULTS

During the study period, 195 events of SAB were identified. A total of 11 patients (5.6%) were excluded: 6 patients died within 48 h, and 5 patients were lost to follow-up. A total of 184 patients were included in the final analysis. Of these, 148 (80.0%) had 1 risk factor or more for metastatic infection and were classified as high-risk SAB. <sup>18</sup>F-FDG PET/CT was performed in 99 of 148 (66.9%) high-risk SAB cases. In addition, <sup>18</sup>F-FDG PET/CT was performed in 6 of 36 (16.7%) patients without risk factors for metastatic infection.

Definite endocarditis according to the modified Duke criteria was diagnosed in 16 patients (8.7%). Forty-six patients (25.0%) were admitted to the intensive care unit within 24 h before and 1 wk after SAB onset. Of 184 *S. aureus* strains isolated, only 5 (2.7%) were methicillin-resistant. Central venous catheter infection was considered responsible for 35 episodes (19.0%) of SAB. Baseline characteristics of all patients with and without <sup>18</sup>F-FDG PET/CT are shown in Table 1.

### Detection of Metastatic Infection by <sup>18</sup>F-FDG PET/CT

<sup>18</sup>F-FDG PET/CT was performed in 105 of 184 study patients at a median of 8.0 d (mean, 8.7 d) after the first blood culture became

positive. In 5 of 6 patients without risk factors for metastatic infection in whom <sup>18</sup>F-FDG PET/CT was performed, no metastatic infection was found on <sup>18</sup>F-FDG PET/CT. In 1 patient with a history of portal vein thrombosis, without risk factors for metastatic infection and removal of a central venous catheter 1 d after positive blood cultures, <sup>18</sup>F-FDG PET/CT was performed and detected septic thrombophlebitis. This patient received intravenous antibiotic treatment for 6 wk. <sup>18</sup>F-FDG PET/CT detected metastatic infectious foci in 73 of 99 patients with high-risk bacteremia (73.7%). In 52 of these 73 patients (71.2%) eventually diagnosed with metastatic infection, no signs and symptoms suggesting metastatic complications were present before <sup>18</sup>F-FDG PET/CT was performed. Metastatic infection was most often diagnosed in the lungs, skin, and soft tissue, and as osteoarticular foci (Table 2). Of all 73 patients with metastatic infection, 47 patients (64.4%) were diagnosed with metastatic foci in more than 1 organ system. Eighteen patients had increased <sup>18</sup>F-FDG uptake in a cardiac valve suspected for endocarditis, of whom 5 had a definite endocarditis according to the modified Duke criteria, 10 had a possible endocarditis, and in 3 patients the diagnosis of endocarditis was rejected.

### Patient Outcome

The relapse rate 3 mo after treatment discontinuation was 2.2% (4/184). Overall 3-mo mortality was 18.5% (34/184). In the univariate analysis, age (59 vs. 69 y,  $P < 0.05$ ), intensive care admission (22.0% vs. 38.2%,  $P < 0.05$ ), Charlson comorbidity score (4.3 vs. 6.5,  $P < 0.05$ ), and no <sup>18</sup>F-FDG PET/CT performed (38.0% vs. 64.7%,  $P = 0.005$ ) were significantly different between survivors and nonsurvivors.

### Patients with Risk Factors for Metastatic Infection

The group with a risk factor for metastatic infection who did not undergo <sup>18</sup>F-FDG PET/CT (risk+/PET-) was compared with the group of patients with a risk factor for metastatic infection and an

**TABLE 2**  
Localization of Metastatic Foci and Number of Foci First Detected by <sup>18</sup>F-FDG PET/CT in 99 High-Risk SAB Patients

Metastatic foci identified	Total	First detected by <sup>18</sup> F-FDG PET/CT
Vertebral osteomyelitis/spondylodiscitis	14	8 (57.1)
Arthritis or joint prosthesis	19	7 (36.8)
Nonvertebral osteomyelitis	10	4 (40.0)
Skin and soft tissue	31	20 (64.5)
Psoas abscess	7	3 (42.9)
Lung	31	17 (54.8)
Spleen	5	5 (100.0)
Liver/gallbladder	3	2 (66.7)
Kidney	1	1 (100.0)
Endocarditis	18	11 (61.1)
Endovascular infection (excluding endocarditis)	20	15 (75.0)
Pericarditis or mediastinitis	4	3 (75.0)
Total	164	97 (59.1)

Data in parentheses are percentages.

**TABLE 3**  
 Characteristics of Patients with 1 or More Risk Factors for Metastatic Infection in Whom <sup>18</sup>F-FDG PET/CT Was Performed (PET+) or Not (PET-)

Characteristic	PET- (n = 49)	PET+ (n = 99)	P
Male	32 (65.3)	60 (60.6)	0.579
Mean age ± SD (y)	60.33 ± 14.2	60.61 ± 16.3	0.714
<b>Risk factors</b>			
Treatment delay > 48 h*	9 (22.0)	36 (43.4)	0.020
Fever > 72 h after treatment initiation†	13 (27.7)	43 (45.3)	0.043
Persistent positive blood cultures > 48 h after treatment initiation‡	7 (15.6)	32 (32.7)	0.033
Community-acquired bacteremia	31 (63.3)	88 (88.9)	<0.001
Foreign body material present	15 (30.6)	46 (46.5)	0.065
ID specialist consultation	30 (61.2)	89 (89.9)	<0.001
Echocardiography¶	20 (40.8)	90 (90.9)	<0.001
Charlson comorbidity score ± SD	5.12 ± 3.4	4.43 ± 2.9	0.314
Intensive care admission	14 (28.6)	26 (26.3)	0.766
<b>3-mo outcome</b>			
Death	16 (32.7)	12 (12.1)	0.003
Recurrent infection	0	3 (3.0)	0.560

\*No data available in 16 patients.

†No data available in 7 patients.

‡No follow-up blood cultures performed in 5 patients.

¶Either transthoracic echocardiography or transesophageal echocardiography.

Data in parentheses are percentages.

<sup>18</sup>F-FDG PET/CT performed (risk+/PET+) (Table 3). In patients with risk factors for metastatic infection in whom <sup>18</sup>F-FDG PET/CT was performed, 3-mo mortality was significantly lower than in the risk+/PET- group (12.1% vs. 32.7%, *P* = 0.003). Multivariate analysis of risk factors for 3-mo mortality in the high-risk group is shown in Table 4. <sup>18</sup>F-FDG PET/CT was the only factor that was significantly associated with reduced mortality (*P* = 0.005; odds ratio, 0.204; 95% confidence interval, 0.066–0.624).

A higher comorbidity score was significantly associated with increased mortality (*P* = 0.003; odds ratio, 1.254; 95% confidence interval, 1.078–1.457).

#### Treatment Modifications in High-Risk Patients

In the 99 patients with high-risk SAB who underwent <sup>18</sup>F-FDG PET/CT, 104 treatment modifications were made in 74 patients (74.7%) after the results of <sup>18</sup>F-FDG PET/CT became available

**TABLE 4**  
 Univariate and Multivariate Analysis of Risk Factors for 3-Month Mortality in Patients with 1 or More Risk Factors for Metastatic Infection (n = 148)

Characteristic	Alive at 3 mo follow-up (n = 120)	Death at 3-mo follow-up (n = 28)	Univariate analysis <i>P</i>	Multivariate analysis <i>P</i>	Odds ratio in multivariate analysis
Male	67 (60.8)	19 (67.9)	0.490		
Echocardiography performed	91 (75.8)	19 (67.9)	0.384		
Composite risk score ± SD*	1.65 ± 1.14	1.93 ± 1.09	0.067	0.052	1.537 (95% CI, 0.997–2.371)
Charlson comorbidity score ± SD	4.24 ± 2.90	6.46 ± 3.49	0.002	0.003	1.254 (95% CI, 1.078–1.457)
<sup>18</sup> F-FDG PET/CT performed	87 (72.5)	12 (42.9)	0.003	0.005	0.204 (95% CI, 0.066–0.624)
ID specialist consultation	99 (82.5)	20 (71.4)	0.184	0.786	0.851 (95% CI, 0.266–2.721)
Intensive care unit admission	29 (24.2)	11 (39.3)	0.105	0.125	2.147 (95% CI, 0.809–5.698)

\*Composite risk score: community-acquisition, persistent fever > 72 h, and skin findings suggesting presence of metastatic infection were separately scored as 1 point, and positive follow-up blood culture results were scored as 2 points (3).

CI = confidence interval.

Data in parentheses are percentages, unless otherwise specified.

**TABLE 5**Treatment Modifications in 99 Patients with High-Risk SAB Based on <sup>18</sup>F-FDG PET/CT Results

Treatment modification	<i>n</i>
Extension of treatment	
Prolonged intravenous antibiotic therapy	15 (15.2)
Addition of a second antimicrobial drug	10 (10.1)
Extension of treatment duration	35 (35.3)
Surgical or radiologic intervention	19 (19.2)
Shortening of treatment duration	25 (25.3)
No treatment modification	25 (25.3)

Data in parentheses are percentages.

(Table 5). In 22 patients (22.2%), more than 1 treatment modification was made. In 25 patients (25.3%), treatment duration was shortened because no metastatic infection was detected. In 15 patients (15.2%), intravenous antibiotic therapy was prolonged on the basis of the <sup>18</sup>F-FDG PET/CT results, in 10 patients (10.1%) a second antimicrobial drug was prescribed, and in 35 patients (35.4%) the total treatment duration was extended. In most cases, treatment was extended because of bone or joint involvement (22.2%), vascular prosthesis


infection (19.4%), or other endovascular infection (17%). Percutaneous or surgical drainage was performed in 19 patients (19.2%) on the basis of the outcome of <sup>18</sup>F-FDG PET/CT (Figs. 1 and 2). No treatment modification was made in 25 patients (25.3%) (Table 5).

Of all patients with a planned treatment duration of 6 wk or more before <sup>18</sup>F-FDG PET/CT was performed, 1 or more treatment modifications were performed in 23 of 46 patients (50.0%) on the basis of <sup>18</sup>F-FDG PET/CT results (Fig. 3), compared with 51 of 53 (96.2%) in the group with a planned treatment duration of less than 6 wk.


The following relevant diseases not related to SAB were diagnosed in 7 patients (7.1%): pulmonary carcinoma, mediastinal carcinoid tumor, recurrent adenocarcinoma of the rectum, recurrent vaginal carcinoma, benign thyroid adenoma, inflammatory bowel disease, and esophageal candidiasis. Irrelevant findings were found in 8 patients: in these patients 2 colonoscopies, 3 esophago-gastro-duodenoscopies, 3 ultrasounds, and 1 CT scan were obtained without a clear diagnosis.

## DISCUSSION


In this study, we investigated the value of <sup>18</sup>F-FDG PET/CT in patients with SAB for detecting metastatic infection and its role in treatment modification in these patients. In a previous prospective study on 115 patients with high-risk Gram-positive bacteremia (9), the addition of <sup>18</sup>F-FDG PET/CT to standard care led to significantly more patients who were diagnosed with metastatic infection



**FIGURE 1.** Transverse <sup>18</sup>F-FDG PET/CT images at level of celiac trunk (left) and maximum-intensity-projection image (right) of 60-y-old man who was admitted because of septic arthritis of his right knee. Blood cultures grew methicillin-susceptible *S. aureus*. Transesophageal echocardiography was negative for endocarditis. Besides an arthritis of his right knee, <sup>18</sup>F-FDG PET/CT also showed a mycotic aneurysm of celiac trunk (arrows) and multiple small abscesses in liver and spleen. This patient underwent a surgical repair of celiac trunk and was successfully treated with flucloxacillin intravenously for 6 wk after surgery.



**FIGURE 2.** <sup>18</sup>F-FDG PET/CT images of 84-y-old woman with right-sided closed humerus fracture after a fall. Two weeks later, she developed arthritis of her left metacarpophalangeal joints and blood cultures were positive for methicillin-susceptible *S. aureus*. Transesophageal echocardiography was negative for endocarditis. Besides arthritis of her left metacarpophalangeal joints, <sup>18</sup>F-FDG PET/CT also showed metastatic infection in her right hip prosthesis, left ankle, right humerus with surrounding abscesses, and lumbar spine (L4–L5) with a right psoas abscess. This patient underwent CT-guided drainage of psoas abscess and was treated with cephazolin, because of allergy to flucloxacillin.



**FIGURE 3.**  $^{18}\text{F}$ -FDG PET/CT images in combination with contrast-enhanced CT images (lower left) of 75-y-old man with medical history of chronic obstructive pulmonary disease, right femoropopliteal bypass, and aortobifemoral bypass who was admitted because of fever. Blood cultures were positive for methicillin-susceptible *S. aureus*. Transesophageal echocardiography was negative for endocarditis.  $^{18}\text{F}$ -FDG PET/CT showed infected right iliac vascular prosthesis. This patient was treated with antibiotic therapy for 5 mo, and because of extensive infection he finally underwent vascular surgery.

compared with a matched historical control group of 230 patients in whom no  $^{18}\text{F}$ -FDG PET/CT was performed (67.8% vs. 35.7% in the control group). Furthermore, 6-mo mortality rate decreased from 32.2% to 19.1% when  $^{18}\text{F}$ -FDG PET/CT was performed. An explanation for the slightly higher detection level in our study (73.7%) could be the fact that metastatic infection is more often seen in SAB than in other types of Gram-positive bacteremia. Another study on the value of  $^{18}\text{F}$ -FDG PET/CT for the diagnosis of metastatic infection in 47 patients with infectious endocarditis found that  $^{18}\text{F}$ -FDG PET/CT was associated with a 2-fold reduction in the number of relapses and  $^{18}\text{F}$ -FDG PET/CT enabled significantly more infectious complications to be diagnosed (57.4% vs. 18% in matched controls) (10). Orvin et al. (15) prospectively studied the value of  $^{18}\text{F}$ -FDG PET/CT in 40 consecutive patients with definite endocarditis according to the Duke criteria.  $^{18}\text{F}$ -FDG PET/CT demonstrated extracardiac complications in 17 patients (42.5%), and these findings led to a change of treatment in 14 patients (35%) while these patients already had an indication for prolonged antibiotic treatment because of endocarditis. This is comparable to our results, because treatment was still adapted in 50% of patients with an indication for prolonged treatment before  $^{18}\text{F}$ -FDG PET/CT was performed.

In the present study, the early detection of metastatic infectious foci facilitated the adaptation of treatment in patients at high risk of relapse. The 3-mo relapse rate was only 2.2%, which is low compared with the rates reported in the literature for complicated SAB (2.1%–23%) (16). An important finding of the present study is that patients with risk factors for metastatic infection who did

not undergo  $^{18}\text{F}$ -FDG PET/CT had a significantly higher mortality rate than those who underwent  $^{18}\text{F}$ -FDG PET/CT (32.7% vs. 12.1%,  $P = 0.003$ ), even though the average number of risk factors for metastatic infection in the latter group was higher. This emphasizes the importance of the risk assessment for metastatic infection and suggests that physicians should not refrain from ordering  $^{18}\text{F}$ -FDG PET/CT with high-risk SAB based on personal judgment. Early death may be hypothesized to be a confounding factor, because those patients were unable to undergo  $^{18}\text{F}$ -FDG PET/CT. However, in a sensitivity analysis excluding patients who died within 7 d after admission, the results regarding 3-mo mortality were similar. Another potential confounder could be the difference in ID specialist consultation, because ID consults have been associated with reduced mortality in patients with SAB (5,17–21). However, multivariate logistic regression analysis did not show this to be an independent predictor of survival, probably due to the high frequency of ID consultation in both groups in the present study. In our study,  $^{18}\text{F}$ -FDG PET/CT detected endocarditis in 18 patients and was the first imaging technique detecting endocarditis in 11 patients. In contrast, 8 patients were diagnosed with a definite endocarditis according to the modified Duke criteria but had a negative  $^{18}\text{F}$ -FDG PET/CT result. Whether  $^{18}\text{F}$ -FDG PET/CT could be used for diagnosing native valve endocarditis needs further investigation, because small studies performed on this subject show limited evidence (22).

Our study has several limitations. First, this is a single-center study that was not prospectively conducted. In 26.6% of patients,  $^{18}\text{F}$ -FDG PET/CT was indicated but not performed. The reasons for nonadherence to the local guidelines are not known, and this could potentially have led to selection bias. Second, although we used a 2-reviewer adjudication process to determine treatment modification, it is possible that misclassification occurred. To reduce bias, the 2 reviewers were masked from each other and disagreements were resolved by a third experienced reviewer.

## CONCLUSION

The performance of  $^{18}\text{F}$ -FDG PET/CT is significantly associated with reduced mortality in patients with high-risk SAB and leads to the detection of metastatic infectious foci in 73.7% of patients, resulting in important treatment modifications.  $^{18}\text{F}$ -FDG PET/CT should be recommended as a standard imaging technique for all patients with 1 or more risk factors for metastatic infection in SAB guidelines.

## DISCLOSURE

No potential conflict of interest relevant to this article was reported.

## REFERENCES

- van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in *Staphylococcus aureus* bacteremia. *Clin Microbiol Rev.* 2012;25:362–386.
- Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of *Staphylococcus aureus* bacteremia: a prospective study of 278 cases. *Arch Intern Med.* 2002;162:25–32.
- Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated *Staphylococcus aureus* bacteremia. *Arch Intern Med.* 2003;163:2066–2072.
- Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of *Staphylococcus aureus* bacteremia according to compliance with recommendations of infectious disease specialists: experience with 244 patients. *Clin Infect Dis.* 1998;27:478–486.

5. Jenkins TC, Price CS, Sabel AL, Mehler PS, Burman WJ. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2008;46:1000–1008.
6. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to *Staphylococcus aureus*: evaluation of different clinical case definitions. *Clin Infect Dis*. 1993;16:567–573.
7. Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of *S. aureus* bacteremia and infectious diseases specialist consultation: a study of 521 patients in Germany. *J Infect*. 2009;59:232–239.
8. Cuijpers ML, Vos FJ, Bleeker-Rovers CP, et al. Complicating infectious foci in patients with *Staphylococcus aureus* or *Streptococcus* species bacteraemia. *Eur J Clin Microbiol Infect Dis*. 2007;26:105–113.
9. Vos FJ, Bleeker-Rovers CP, Sturm PD, et al. <sup>18</sup>F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. *J Nucl Med*. 2010;51:1234–1240.
10. Kestler M, Munoz P, Rodriguez-Creixems M, et al. Role of <sup>18</sup>F-FDG PET in patients with infectious endocarditis. *J Nucl Med*. 2014;55:1093–1098.
11. Vos FJ, Bleeker-Rovers CP, Kullberg BJ, Adang EM, Oyen WJ. Cost-effectiveness of routine <sup>18</sup>F-FDG PET/CT in high-risk patients with gram-positive bacteremia. *J Nucl Med*. 2011;52:1673–1678.
12. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol*. 2004;57:1288–1294.
13. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis*. 2000;30:633–638.
14. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by The Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52:e18–e55.
15. Orvin K, Goldberg E, Bernstine H, et al. The role of FDG-PET/CT imaging in early detection of extra-cardiac complications of infective endocarditis. *Clin Microbiol Infect*. 2015;21:69–76.
16. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, et al. Clinical management of *Staphylococcus aureus* bacteraemia. *Lancet Infect Dis*. 2011;11:208–222.
17. Choi SH, Cho SY, Park JH, Chung JW. Impact of infectious-disease specialist consultations on outcomes of *Staphylococcus aureus* bacteremia in a hospital with a low volume of patients with *S. aureus* bacteremia. *J Infect*. 2011;62:181–185.
18. Forsblom E, Ruotsalainen E, Ollgren J, Jarvinen A. Telephone consultation cannot replace bedside infectious disease consultation in the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2013;56:527–535.
19. Fries BL, Licitra C, Crespo A, et al. Infectious diseases consultation and the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2014;58:598–599.
20. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in *Staphylococcus aureus* bacteremia. *Am J Med*. 2010;123:631–637.
21. Lahey T, Shah R, Gitzus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from *Staphylococcus aureus* bacteremia. *Medicine (Baltimore)*. 2009;88:263–267.
22. Gomes A, Glaudemans AWJM, Touw DJ, et al. Diagnostic value of imaging in infective endocarditis: a systematic literature review and a proposal of an updated diagnostic work-up. *Lancet Infect Dis*. 2017;17:e1–e14.